Light rail extension between Seattle and Eastside delayed
We'll have to wait a little longer for a light rail extension between Seattle and the Eastside.
The project was supposed to be finished by the end of 2025, but it's now being pushed back to 2026.
An exact time frame hasn't yet been announced.
Last week, crews successfully pulled a light rail car across the new tracks along the I-90 floating bridge over Lake Washington.
It will be the first light rail to run across a floating bridge.
Crews have been working to finish rail installation and testing the electrical systems along the track.
During final rail installation, where the tracks are anchored to the concrete support blocks below them, crews found that a small number of the bolt inserts within the blocks need replacement.
'While not concerning based on what we know today, we want to get those connectors replaced now,' a news release from Sound Transit says.
Crews also want to make sure that bringing the electrified light rail across the bridge won't damage its existing structure.
Testing is expected to last through the summer.
The Downtown Redmond Link Extension opened May 10.
Ten of the 12 stations on the 2-Line are now open.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Los Angeles Times
13 hours ago
- Los Angeles Times
A trip to LAX without a car? Metro opens long-awaited LAX station
Decades after rail first broke ground in Los Angeles County, Angelenos will be one step closer to an airport connection with Friday afternoon's opening of the LAX/Metro transit center. The station at Aviation Boulevard and 96th Street will connect to the K Line and C Line and, starting next year, to Los Angeles International Airport's long-awaited automated people mover train. For now, free shuttle buses running every 10 minutes will transport travelers along the 2.5-mile route between the center and LAX. The transit center was budgeted at $900 million and includes a 16-bay bus plaza with electric bus infrastructure, a bicycle hub and a pickup and drop-off area for those who want to avoid the airport's traffic-choked horseshoe loop. Metro parking lots near the station will offer short-term parking. A ribbon cutting is planned for 1 p.m. to commemorate the center's launch and Metro is offering free rides across its system through the weekend. The station opens to the public at 5 p.m. 'When the people mover finally opens, then we will have an international airport that will connect people from literally inside the terminals to the world and beyond through Metro,' Sup. Janice Hahn said during a Metro board of directors meeting in April. From downtown, travelers headed to the transit center would board the A Line to the C Line or the E Line to the K Line. In other areas, including Redondo Beach, Norwalk, Leimert Park and Inglewood, travelers could use one line; in Pasadena and Long Beach, they would need two; those headed from Hollywood or Universal Studios would need to take three trains. Most major cities already have a direct airport rail connection. The absence at LAX has long left travelers baffled, particularly first-time visitors and international passengers expecting a world destination like Los Angeles to have streamlined transit to its main airport. A variety of factors led to the delay, including reported concerns among airport officials over potential lost parking profits, Federal Aviation Administration pushback, and competing interests over taxpayer dollars. The debate was renewed more than a decade ago and plans for the airport's people mover connection and Metro's station were ultimately approved. The station is one of Metro's '28 by 28' transit projects ahead of the Olympics. 'It was such a black eye on the system and on the rail leaders that they couldn't connect Metro rail to LAX,' said Ethan Elkind, a rail expert who authored 'Railtown: The Fight for the Los Angeles Metro Rail and the Future of the City.' He added that the station and the upcoming train 'fills in this big missing gap in the system.' Elkind said it's unclear how many residents will end up relying on the train entirely to get to the airport if they have to change lines while balancing luggage or kids. But it will likely help the employees who make the trek to the airport every day. Tens of thousands of people work at the airport, on top of the hundreds of thousands of weekly travelers. The train is the most anticipated project under the airport's $30 billion overhaul ahead of the FIFA World Cup in 2026 and the Olympics and Paralympics in 2028. Airport leaders and transit experts believe the automated train will significantly ease traffic at 1 World Way.
Yahoo
17 hours ago
- Yahoo
Immix Biopharma Attends FDA CEO Forum in Washington DC
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ('ImmixBio', 'Company', 'We' or 'Us' or 'IMMX'), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters in Silver Spring, MD, on June 5, 2025. Per FDA, the purpose of the meeting is to gather direct input from biotechnology and pharmaceutical leaders on how the FDA can modernize its regulatory framework to better support innovation and patient access to safe and effective therapies. FDA Commissioner Marty A. Makary, M.D., M.P.H. stated, 'These CEO Forums are a chance for the FDA to listen and gather feedback from those at the front lines of discovery. We are committed to strengthening a regulatory environment that enables breakthroughs to reach patients faster, while upholding the highest standards of safety and scientific integrity.' 'We share FDA's vision for an efficient, thoughtful regulatory framework to accelerate patient access to safe and effective therapies. Discussing this topic with FDA Commissioner Dr. Makary and team yesterday offered an unprecedented opportunity,' said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, 'As we progress, we were thrilled to be selected alongside other leaders of the global pharmaceutical industry. We are grateful that FDA facilitated this important, collaborative discussion.' About Immix Biopharma, Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as 'expects', 'contemplates', 'anticipates', 'plans', 'intends', 'believes', 'estimates', 'potential', and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section 'Risk Factors' included in the Company's Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@ Company Contactirteam@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
